Gregory Duncan has been a director of CorMedix since November 2020. Mr. Duncan currently serves as the Chairman and CEO of Dogwood Therapeutics, Inc. (Nasdaq: DWTX), a clinical -stage biopharmaceutical company developing and commercializing innovative new medicines to treat pain and neuropathy. The Dogwood research pipeline includes two first -in-class development candidates, Halneuron and SP16. Halneuron is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. SP 16 is a low -density lipoprotein receptor related protein -I agonist (LRPl) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. DWTX was formed through the integration of Virios Therapeutics, Inc., where Mr. Duncan has served as CEO and Chairman since 2020, and Wex Pharmaceuticals, in October 2024. From 2014 and prior to joining his current company, Mr. Duncan served as President and CEO of Celtaxsys, a privately held biotechnology company focused on cystic fibrosis and other rare, inflammatory diseases. Mr. Duncan has spent the majority of his career in senior leadership roles in commercial stage pharmaceutical companies. From 2007 to 2013, he served as an executive committee member at UCB, including as President of its North American operations. Prior to his roles with UCB, Mr. Duncan spent approximately 17 years at Pfizer where he gained significant experience across sales, marketing and development functions including serving as SVP of US Marketing and as President of Pfizer s Latin America business from 2005 to 2007. Mr. Duncan received his undergraduate degree from the State University of New York, Albany, and earned an MBA degree from Emory University. Among other experience, qualifications, attributes and skills, Mr. Duncan s significant depth of experience in the pharmaceutical industry led to the conclusion of the Board that he should serve as a director of our Company considering our business and structure.